JR Rahn is stepping down as MindMed's CEO, to be replaced by Chief Development Officer, Robert Barrow.
Mydecine Discovers Over 40 Groundbreaking Potential Pharmacologically Active Novel Compounds in Mushrooms
Mydecine announces identifying 40 previously unknown "novel compounds" among dozens of mushroom species it has screened.
Cybin Launches EMBARK and Co-Sponsors First Clinical Trial to Treat Frontline Clinicians Experiencing COVID-Related Burnout and Distress with Psychedelic-Assisted Psychotherapy
Cybin is launching a new clinical trial to address "COVID-related burnout and distress", supported by its new EMBARK psychotherapy model.
Red Light Holland Closes Acquisition of Cutting Edge Silicon Valley Applied Sciences Company Radix Motion, Becoming a Leader in Psychedelic Technology
Red Light Holland's new tech acquisition is intended to help optimize psychedelics dosing.
Optimi Health Announces Product Distribution Agreement with Vitasave
Optimi Health's new distribution agreement with Vitasave provides retail access to two of Canada's largest urban markets.
Field Trip Health Ltd. Applies to List Its Common Shares on the NASDAQ Stock Market
After just uplisting to the TSX in Canada, Field Trip Health has applied to uplist to the NASDAQ in the U.S.
Are Psychedelics The Ultimate Brain-Repair Drugs?
Psychedelic drugs increasingly appear to be powerful medicinal tools to rebuild broken brains.
Field Trip Virtually Opens The Market
Field Trip Health has uplisted to the TSX in Canada.
American Support For And Understanding Of Psychedelic Drugs Continues To Broaden
A Psychedelic Drug Revolution is underway to address the Mental Health Crisis. As with all revolutions, we are seeing a rapid shift in attitudes.
Texas Bills To Require Psychoactive Drug Study Head To Governor’s Desk
In the final days of Texas’s legislative session, lawmakers sent bills to the governor’s desk that would require a study into the therapeutic potential of certain psychedelics for military veterans.
Novamind Reports Fiscal Q3 Financial Results and Operating Highlights
Novamind's clinic revenues jumped 43% quarter-over-quarter, to CAD$1.85 million. Projecting a 225% increase in clinic visits year-over-year.
Psychedelic Drug Stocks: A BIG Healthcare Footprint At A SMALL Price
The psychedelic drug industry already has a large footprint in healthcare. And it is growing in literally every direction.
